AR059922A1 - Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos - Google Patents

Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Info

Publication number
AR059922A1
AR059922A1 ARP070101084A ARP070101084A AR059922A1 AR 059922 A1 AR059922 A1 AR 059922A1 AR P070101084 A ARP070101084 A AR P070101084A AR P070101084 A ARP070101084 A AR P070101084A AR 059922 A1 AR059922 A1 AR 059922A1
Authority
AR
Argentina
Prior art keywords
growth factor
hepatocits
monoclonal antibodies
humanized monoclonal
pharmaceutical composition
Prior art date
Application number
ARP070101084A
Other languages
English (en)
Spanish (es)
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of AR059922A1 publication Critical patent/AR059922A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP070101084A 2006-04-01 2007-03-16 Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos AR059922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01

Publications (1)

Publication Number Publication Date
AR059922A1 true AR059922A1 (es) 2008-05-07

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101084A AR059922A1 (es) 2006-04-01 2007-03-16 Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Country Status (25)

Country Link
US (3) US7632926B2 (enExample)
EP (2) EP2016162B1 (enExample)
JP (1) JP5312315B2 (enExample)
KR (1) KR101516289B1 (enExample)
CN (2) CN103172736A (enExample)
AR (1) AR059922A1 (enExample)
AU (1) AU2007233242B2 (enExample)
BR (1) BRPI0709932A2 (enExample)
CA (1) CA2645358C (enExample)
CO (1) CO6140067A2 (enExample)
CR (1) CR10308A (enExample)
ES (1) ES2465668T3 (enExample)
GE (1) GEP20125517B (enExample)
IL (1) IL194221A (enExample)
MA (1) MA30382B1 (enExample)
MX (1) MX2008012619A (enExample)
MY (1) MY145042A (enExample)
NO (1) NO20084539L (enExample)
NZ (1) NZ571132A (enExample)
PE (1) PE20080008A1 (enExample)
RU (1) RU2461570C2 (enExample)
TW (1) TWI417300B (enExample)
UA (1) UA94452C2 (enExample)
WO (1) WO2007115049A2 (enExample)
ZA (1) ZA200807903B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
JP2008545753A (ja) * 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
PL2032166T3 (pl) * 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
EP2636513B1 (en) * 2008-04-10 2014-08-27 Stratasys Ltd. System and method for three dimensional model printing
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
WO2009126840A1 (en) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
JP5699075B2 (ja) * 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
US8101725B2 (en) 2008-05-29 2012-01-24 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
DK2842573T3 (en) 2008-11-07 2017-10-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
EP2360183B1 (en) 2008-12-19 2016-07-27 Takeda Pharmaceutical Company Limited Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
CA2763488A1 (en) * 2009-05-28 2010-12-02 Neil James Clarke Antigen-binding proteins
RS66008B1 (sr) 2010-03-10 2024-10-31 Genmab As Monoklonska antitela protiv c-met
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
EP2753357A1 (en) 2011-09-09 2014-07-16 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
CN105246915A (zh) * 2013-03-14 2016-01-13 奥尔德生物制药公司 Hgf抗体及含有其的组合物
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2017075484A2 (en) 2015-10-30 2017-05-04 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4 and death receptor 5
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
EP4013869A1 (en) 2019-08-12 2022-06-22 InteRNA Technologies B.V. New treatments involving mirna-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE69739856D1 (de) * 1996-07-03 2010-06-02 Genentech Inc Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
EP1183275B1 (en) * 1999-05-17 2006-08-09 Avi Biopharma, Inc. Specific antibodies against human chorionic gonadotropin and their use in therapy and diagnostic
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
AU2002355249A1 (en) 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2367008A3 (en) 2003-06-06 2014-12-24 Genentech, Inc. Modulating the interaction between HGF beta chain and C-Met
WO2005007193A2 (en) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
KR20060079227A (ko) 2003-09-18 2006-07-05 코닌클리케 필립스 일렉트로닉스 엔.브이. 정보매체와, 그 정보매체에 저장된 데이터 판독 시스템
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005079489A2 (en) * 2004-02-17 2005-09-01 Science & Technology Corporation @ Unm Method of treating cancer and identifying novel anti-ancer compounds
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
JP2008545753A (ja) 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
WO2007056523A2 (en) 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
US20080019974A1 (en) 2008-01-24
US20140335076A1 (en) 2014-11-13
BRPI0709932A2 (pt) 2011-08-02
NO20084539L (no) 2008-10-28
JP2009532378A (ja) 2009-09-10
CN101415811A (zh) 2009-04-22
WO2007115049A2 (en) 2007-10-11
CO6140067A2 (es) 2010-03-19
NZ571132A (en) 2012-05-25
WO2007115049A3 (en) 2008-09-04
CR10308A (es) 2008-10-27
EP2476704A3 (en) 2012-07-25
US20100278815A1 (en) 2010-11-04
EP2476704A2 (en) 2012-07-18
ES2465668T3 (es) 2014-06-06
EP2016162A4 (en) 2009-11-11
RU2461570C2 (ru) 2012-09-20
US8628778B2 (en) 2014-01-14
AU2007233242B2 (en) 2012-04-26
CA2645358C (en) 2015-05-05
CN103172736A (zh) 2013-06-26
TW200808828A (en) 2008-02-16
MY145042A (en) 2011-12-15
MA30382B1 (fr) 2009-05-04
HK1121489A1 (en) 2009-04-24
ZA200807903B (en) 2010-03-31
KR101516289B1 (ko) 2015-05-07
AU2007233242A1 (en) 2007-10-11
UA94452C2 (ru) 2011-05-10
US7632926B2 (en) 2009-12-15
JP5312315B2 (ja) 2013-10-09
EP2016162A2 (en) 2009-01-21
PE20080008A1 (es) 2008-02-14
TWI417300B (zh) 2013-12-01
MX2008012619A (es) 2008-10-13
KR20090013777A (ko) 2009-02-05
CA2645358A1 (en) 2007-10-11
CN101415811B (zh) 2013-01-30
GEP20125517B (en) 2012-05-25
RU2008143318A (ru) 2010-05-10
EP2016162B1 (en) 2014-04-16
IL194221A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
CL2007002404A1 (es) Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
BR112013032456A2 (pt) anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
EA201100884A1 (ru) Моноклональные антитела анти-rhd
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
BRPI0813145A2 (pt) anticorpo modificado, composição, e, método de tratamento de um paciente humano
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal